| Literature DB >> 31891450 |
Komal Agarwal1, Indrashis Podder2, Martin Kassir3, Aleksandra Vojvodic4, Robert A Schwartz5, Uwe Wollina6, Yan Valle7, Torello Lotti8, Ghasem R Rokni9, Stephan Grabbe10, Mohamad Goldust11,12,13.
Abstract
Vitiligo is a relatively common disorder characterized by areas of depigmented skin. It may be associated with social stigma and adversely affects the quality of life. Although many treatment options are available, none is curable. The search continues for an effective therapeutic option. New targeted options include biologics and other immunomodulatory agents, with varying degrees of evidence. We have discussed briefly the therapeutic options with special emphasis on the newer immunomodulatory agents. We undertook a comprehensive English literature search across multiple databases such as PubMed, SCOPUS, EMBASE, MEDLINE, and Cochrane using keywords (alone and in combination) and MeSH items such as "vitiligo," "treatment," "recent," and "immunomodulators" to obtain several relevant articles, priority being given to prospective randomized controlled trials. We scanned all the relevant articles and summarized them to obtain the latest information about the treatment of this condition to prepare the current article.Entities:
Keywords: immunomodulators; new treatment; vitiligo
Mesh:
Substances:
Year: 2020 PMID: 31891450 DOI: 10.1111/dth.13215
Source DB: PubMed Journal: Dermatol Ther ISSN: 1396-0296 Impact factor: 2.851